Showing 501-510 of 7600 results for "".
Merz Acquires Ulthera; Ulthera Gets Decolletage Indication, and a New Topical for Onychomycosis
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-merz-acquires-ulthera-ulthera-gets-decolletage-indication-and-a-new-topical-for-onychomycosis/19117/In this edition of DermWireTV, from the publishers of Practical Dermatology® magazine, learn the latest on the Merz/Ulthera acquisition, a new topical for toenail fungus, and FDA accepts Kythera's NDA.In-Review: Two New Melanoma Agents Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/in-review-two-new-melanoma-agents-approved/21534/Utilizing genetic abnormalities, new therapies are carving out new possibilities for melanoma treatment.Skin Resurfacing, Pixel RF from Alma Lasers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/-skin-resurfacing-pixel-rf-from-alma-lasers/19241/Skin resurfacing with the innovative Pixel RF from Alma Lasers. Ready to fight the hands of time? Click here for more info: http://www.AlmaLasers.comVShape Facial Contouring by Alma Lasers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/vshape-facial-contouring-by-alma-lasers/19251/VShape is a non-invasive and pain-free treatment for facial contouring. Performed throughout the world using Alma Lasers Accent Ultra medical aesthetic technology. vShape: Bipolar RF TechnologyFrom Clinic to Capitol: Tips for Building Grassroots and Legislative Support For Anti-Tanning Policies in Your State
https://practicaldermatology.com/topics/skin-cancer-photoprotection/from-clinic-to-capitol-tips-for-building-grassroots-and-legislative-support-for-anti-tanning-policies-in-your-state/22943/It's no easy task to shepherd legislation through state assemblies, but dermatologists' clinical standing can have some influence.All Things Psoriasis With Dr. April Armstrong
https://practicaldermatology.com/series/the-practical-dermatology-podcast/all-things-psoriasis-with-dr-april-armstrong/36135/The latest news and updates, plus April W. Armstrong, MD, MPH, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the current state of psoriasis treatments, what's in the pipeline, her experience in leadership positions for multiple psoriasis organizations, and more.Ask Me Anything: Mona Sadeghpour, MD
https://practicaldermatology.com/youngmd-connect/wrap-ups/ask-me-anything-mona-sadeghpour-md/24215/An intimate YoungMD Connect virtual mentorship event encourages exchange of ideas, advice, and feedback.Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.Treating Severe Acne in Transgender Patients: An Update
https://practicaldermatology.com/columns/clinical-focus-1/treating-severe-acne-in-transgender-patients-an-update/23472/Understanding the implications of isotretinoin use in FTM acne patients.FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/series/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.